Form 4: Vistagen Therapeutics Director Jon S. Saxe Reports Stock Option Grant

Director Jon S. Saxe reports receiving a stock option grant from Vistagen Therapeutics.

Summary

• On September 6, 2024, Jon S. Saxe, a director of Vistagen Therapeutics, Inc., was granted stock options to purchase 14,100 shares of common stock.
• The exercise price of these options is $3.25 per share.
• 25% of the options vest immediately, with the remaining 75% vesting in equal monthly installments over the following year.
• The options expire on September 6, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants, a common practice in incentivizing company directors.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if the director's performance leads to an increase in the company's stock price.

Key Dates